

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
ACQUISITION OF LAND USE RIGHT IN SUZHOU, THE PRC

This announcement is made by the Company on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group. The Company is pleased to announce that on March 4, 2021, the Company entered into the Confirmation Letter with the Planning and Construction Committee, pursuant to which the Planning and Construction Committee has confirmed, and the Company has acknowledged, that the Company has won the bid for the land use right of the Land at a total consideration of RMB7,960,000. As a result of winning the bid, the Company will enter into the Land Use Right Contract with the Planning and Construction Committee on March 11, 2021.

Details of the Confirmation Letter are set out as follows:

Date: March 4, 2021

Parties: (1) The Company; and

(2) The Planning and Construction Committee, being a local government authority under the People's Government of Suzhou Industrial Park, the PRC

Subject matter: The Planning and Construction Committee has confirmed, and the Company has acknowledged, that the Company won the bid for the purchase of land use right of the Land at a total consideration of RMB7,960,000.

The Company has won the bid for the purchase of land use right of the Land at a total consideration of RMB7,960,000. The consideration of RMB7,960,000 for the Land Acquisition has been funded by the Company with the Group's internal resources. In bidding for the Land, the Company has taken into account the minimum bid price, the current market conditions, the location of the Land, and the land price in the surrounding area. The Directors believe that the consideration for the Land is fair and reasonable and in the interests of the Company and the Shareholders as a whole.

INFORMATION OF THE GROUP AND THE PARTIES

The Company is an innovative platform of genetic testing solutions for assisted reproduction in China. The Planning and Construction Committee is local government authority under the Suzhou Industrial Park Administrative Committee and is responsible for, among others, overall planning, detailed planning and infrastructure planning of the Suzhou Industrial Park, including granting land use right in Suzhou Industrial Park. To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, the Planning and Construction Committee and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

REASONS FOR AND BENEFITS OF THE LAND ACQUISITION

The Land is intended to be used for the construction of the headquarters of the Company. The headquarters construction project of the Company is a key project in Suzhou Industrial Park. The planned gross floor area of the project is 71,850 sq.m., with 21,700 sq.m. for research and development office use and 32,800 sq.m. for production use. Acquisition of the Land and the construction of our headquarters on the Land can render better support to the production and operation of the Group. The headquarters building of the Group will also serve as an exchange platform for the field of fertility, facilitate communication with our upstream and downstream enterprises in the field of assisted reproduction and fertility, promote industry development through synergy, and create cluster effect for the next-generation sequencing (NGS) testing industry. The development and construction of the headquarters building and will also be conducive to laying a solid foundation for the existing and future operation of the Group, so that the Group can further improve in the key areas of business operation, including control of product research and development, production, finance and sales. The Company considers that the Land Acquisition and the construction of the headquarters building of the Company will lay a solid foundation for the strategic development of the Group. They are consistent with the Group's development strategies.

Having taken into account the above factors, the Directors believe that the Land Acquisition is beneficial to the Company and the Shareholders as a whole, and the Land is considered suitable to support the business development of the Group. The Directors also consider that the terms of the Confirmation Letter are on normal commercial terms, and are fair and reasonable and in the interest of the Company and the Shareholders as a whole.

LISTING RULES IMPLICATIONS

The Land Acquisition does not constitute a notifiable transaction or connected transaction under Chapter 14 or Chapter 14A of the Listing Rules. This announcement is made by the Company on a voluntary basis.

DEFINITION

“Board”	the board of Directors
“Company”	Suzhou Basecare Medical Corporation Limited (蘇州貝康醫療股份有限公司), a company incorporated in the PRC with limited liability on December 14, 2010 and converted into a joint stock company with limited liability on August 27, 2020
“Confirmation Letter”	the transaction confirmation letter (成交確認書) entered into by the Company and Planning and Construction Committee on March 4, 2021 as a result of the successful bidding by the Company for the land use right of the Land
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Directors”	the directors of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Planning and Construction Committee”	the Suzhou Industrial Park Planning and Construction Committee, a local government authority under the Suzhou Industrial Park Administrative Committee
“Land”	a piece of land for industrial purpose located to the east of Xingtang Street and north of Jiangyun Road, Suzhou Industrial Park, Jiangsu, PRC and is of a total site area of 21,626.14 sq.m.

“Land Acquisition”	the acquisition of the land use right of the Land through a public bidding process at the auction
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended, supplemented or otherwise modified from time to time
“PRC”	the People’s Republic of China, which for the purpose of this announcement, excludes Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“sq.m.”	square metre(s)
“Land Use Right Contract”	the State-owned Construction Land Use Right Grant Contract (國有建設用地使用權出讓合同) to be entered into by the Company pursuant to the Confirmation Letter on March 11, 2021
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, March 4, 2021

As of the date of this announcement, the Board comprises Mr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Mr. KANG Xixiong, Mr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive Directors.